HMGCR and type 2 diabetes mellitus: Since the recognition of this adverse drug event, Swerdlow et al. conducted an MR study to assess whether the increase in new-onset type 2 diabetes risk is a result of the inhibition of HMGCR, i.e. the enzyme targeted by statins.